StocktoriaCadrenal Therapeutics, Inc. CVKD
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Operating income | -$13.5M | -$11.0M | -$7.6M | -$2.7M |
| Net income | -$13.2M | -$10.7M | -$8.4M | -$6.7M |
| Operating cash flow | -$12.6M | -$7.4M | -$3.5M | -$1.2M |
| Free cash flow | -$12.6M | -$7.4M | -$3.5M | -$1.2M |
| Total assets | $4.3M | $10.1M | $8.5M | $778,174 |
| Total liabilities | $1.6M | $2.7M | $826,875 | $6.3M |
| Shareholders' equity | $2.7M | $7.4M | $7.7M | -$5.6M |
| Ratios | ||||
| Return on assets | -305.9% | -105.2% | -98.1% | -862.8% |
| Return on equity | -483.3% | -143.2% | -108.6% | 121.0% |
| Current ratio | 2.72 | 3.77 | 10.27 | 0.55 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001937993 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.